C

    Coherus BioSciences Inc (CHRS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.35
    -0.06 (-4.26%)

    Market Cap: $208.58M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    33%(13/40)
    Avg Surprise
    -2.97%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.21
    Range$-0.21 - $-0.21
    2 analysts
    EPS RevisionsNo revisions (7d)
    2
    0
    30d
    EPS Estimate Drift
    90d ago$-0.25-19.0%
    60d ago$-0.23-7.1%
    30d ago$-0.23-7.1%
    7d ago$-0.23-7.1%
    Current$-0.21
    Revenue Consensus
    $16M
    Range$15M - $17M
    6 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.27
    Range$-0.28 - $-0.25
    2 analysts
    Revenue Consensus
    $10M
    Range$8M - $15M
    6 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.27---
    Sep 26EST
    		-$-0.21---
    Jun 26
    Reported Aug 5
    		$-0.22$-0.16-37.50%Miss+43.6%
    Mar 26
    Reported May 11
    		$-0.25$-0.26+3.85%Beat+28.6%
    Dec 25
    Reported Mar 9
    		$-0.34$-0.34-0.53%Miss-21.4%
    Sep 25
    Reported Nov 6
    		$-0.33$-0.29-13.79%Miss-3200.0%
    Jun 25
    Reported Aug 7
    		$-0.39$-0.25-56.00%Miss-178.6%
    Mar 25
    Reported May 12
    		$-0.35$-0.22-59.09%Miss-9.4%
    Dec 24
    Reported Mar 10
    		$-0.28$-0.13-114.56%Miss+54.8%
    Sep 24
    Reported Nov 6
    		$-0.01N/A+90.91%Beat+96.3%
    Jun 24
    Reported Aug 8
    		$-0.14$-0.26+46.15%Beat+63.2%
    Mar 24
    Reported May 9
    		$-0.32$-0.21-52.38%Miss+60.0%
    Dec 23
    Reported Mar 13
    		$-0.62$-0.12-416.67%Miss-3.3%
    Sep 23
    Reported Nov 6
    		$-0.27$-0.24-12.50%Miss+71.9%
    Jun 23
    Reported Aug 2
    		$-0.38$-0.44+13.64%Beat+19.1%
    Mar 23
    Reported May 8
    		$-0.80$-0.47-70.21%Miss+20.0%
    Dec 22
    Reported Mar 6
    		$-0.60$-0.84+28.57%Beat+0.0%
    Sep 22
    Reported Nov 8
    		$-0.96$-0.61-57.38%Miss-95.9%
    Jun 22
    Reported Aug 4
    		$-0.47$-0.73+35.62%Beat-17.5%
    Mar 22
    Reported May 5
    		$-1.00$-0.65-53.85%Miss-334.8%
    Dec 21
    Reported Feb 17
    		$-0.60$-0.54-11.11%Miss-600.0%
    Sep 21
    Reported Nov 8
    		$-0.49$-0.29-68.97%Miss-248.5%
    Jun 21
    Reported Aug 5
    		$-0.40$-0.15-166.67%Miss-157.1%
    Mar 21
    Reported May 6
    		$-0.23$0.11-309.09%Miss-147.9%
    Dec 20
    Reported Feb 24
    		$0.12$0.23-47.83%Miss-78.6%
    Sep 20
    Reported Nov 5
    		$0.33$0.34-2.94%Miss-47.6%
    Jun 20
    Reported Aug 6
    		$0.70$0.29+141.38%Beat+118.7%
    Mar 20
    Reported May 7
    		$0.48$0.48+0.00%Beat+265.5%
    Dec 19
    Reported Feb 27
    		$0.56$0.72-22.22%Miss+160.9%
    Sep 19
    Reported Nov 6
    		$0.63$0.42+50.00%Beat+172.4%
    Jun 19
    Reported Aug 1
    		$0.32$-0.04+900.00%Beat+147.1%
    Mar 19
    Reported May 9
    		$-0.29$-0.46+36.96%Beat+60.8%
    Dec 18
    Reported Feb 28
    		$-0.92$-0.86-6.98%Miss-9.5%
    Sep 18
    Reported Nov 8
    		$-0.87$-0.79-10.13%Miss+20.2%
    Jun 18
    Reported Aug 8
    		$-0.68$-0.65-4.62%Miss+37.0%
    Mar 18
    Reported May 10
    		$-0.74$-0.70-5.71%Miss+51.9%
    Dec 17
    Reported Mar 8
    		$-0.84$-0.81-3.70%Miss+50.9%
    Sep 17
    Reported Nov 6
    		$-1.09$-0.85-28.24%Miss-165.3%
    Jun 17
    Reported Aug 7
    		$-1.08$-1.39+22.30%Beat-
    Mar 17
    Reported May 8
    		$-1.54$-1.43-7.69%Miss-
    Dec 16
    Reported Mar 13
    		$-1.71$-1.11-54.05%Miss-
    Sep 16
    Reported Nov 9
    		$1.67$-1.57+206.37%Beat-

    Key Metrics

    Valuation
    P/E Ratio-1.18EV/EBITDA1.28x
    Price/FCF-1.12xFCF Yield-89.01%
    Profitability
    Profit Margin-259.40%Operating Margin-226.00%
    ROE-178.40%ROIC-122.48%
    Financial Health
    Debt/Equity0.61xInterest Coverage-16.74x
    Current Ratio1.77xQuick Ratio1.70x
    Trading Statistics
    Beta0.95Avg Volume1.34M
    52-Week High$2.6252-Week Low$1.09

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.38
    SMA 20$1.32
    SMA 50$1.41
    SMA 200$1.57
    EMA 10$1.37
    EMA 20$1.36
    EMA 50$1.41
    EMA 200$1.49

    MACD

    Line: 0.00Signal: -0.02Hist: 0.02

    ADX

    ADX: 15.9+DI: 21.4-DI: 24.3

    Aroon & PSAR

    Aroon Up28.0
    Aroon Down60.0
    PSAR$1.20

    Bollinger Bands

    Upper Band$1.54
    Lower Band$1.10
    %B Position3298%(Upper)
    Band Width0.57

    RSI (14-Day)

    Neutral
    48.8

    Momentum Oscillators

    Stoch %K79.0
    Stoch %D86.3
    Williams %R-37.1
    ROC (10d)17.4%
    Momentum0.20
    CCI (20d)24.4
    MFI (14d)56.8

    Volatility Measures

    ATR (14d)$0.10(7.2%)
    StdDev (20d)0.11
    Hist Vol93.7%(High)

    Volume Flow

    VWAP$1.35
    OBV57.2M
    AD Line-17.4M
    CMF (20d)-0.077

    Volume Metrics

    Avg Vol (20d)1.4M
    Vol Ratio0.8x
    VWMA (20d)$1.31

    Pivot Points

    R3$1.54
    R2$1.51
    R1$1.46
    Pivot Point$1.43
    S1$1.38
    S2$1.35
    S3$1.30

    Advanced Oscillators

    TSI-0.05
    Ultimate Osc56.0
    KST-47.33

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$14.31M$12.31M$12.75M$11.57M$10.25M$7.60M$7.73M$6.05M$10.30M$2.31M$91.52M$74.57M
    Cost of Revenue$4.24M$3.81M$4.04M$3.72M$3.40M$2.65M$2.75M$2.73M$1.81M$1.44M$84.57M$32.70M
    Gross Profit$10.06M$8.50M$8.70M$7.85M$6.86M$4.95M$4.98M$3.32M$8.49M$869,000$6.96M$41.87M
    Operating Expenses$42.40M$44.65M$54.58M$52.18M$52.34M$50.38M$50.37M$50.18M$48.11M$68.66M$75.86M$73.87M
    R&D$21.44M$21.54M$30.97M$27.25M$26.31M$24.36M$20.76M$22.05M$20.60M$28.42M$26.37M$25.65M
    SG&A$20.95M$23.10M$23.61M$24.93M$26.04M$26.02M$29.61M$28.13M$27.52M$40.23M$49.49M$48.22M
    Operating Income$-32,331,000$-36,151,000$-45,880,000$-44,333,000$-45,486,000$-45,435,000$-45,384,000$-46,856,000$-39,626,000$-67,787,000$-68,905,000$-32,006,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$2.32M$2.19M$2.25M$2.33M$2.28M$2.15M$727,000$2.83M$16.69M$3.12M$10.62M$10.27M
    Income Before Tax$-33,347,000$-36,935,000$-46,347,000$-44,517,000$-44,862,000$-47,398,000$-44,908,000$-47,599,000$-54,851,000$-68,036,000$-79,653,000$-40,021,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$-380,000
    Net Income$-20,631,000$-38,327,000$-37,643,000$-35,531,000$297.77M$-56,569,000$-50,696,000$-10,751,000$-12,921,000$102.88M$-79,653,000$-39,641,000
    EBITDA$-30,162,000$-33,868,000$-43,202,000$-41,226,000$-41,569,000$-44,202,000$-43,148,000$-43,223,000$-36,972,000$-63,411,000$-67,971,000$-28,854,000
    EBIT$-31,024,000$-34,749,000$-44,098,000$-42,192,000$-42,585,000$-45,248,000$-44,181,000$-44,772,000$-38,159,000$-64,918,000$-69,034,000$-29,753,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CHRS

    News

    Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights

    Coherus Oncology has announced a special dividend of Contingent Value Rights (CVRs) to shareholders, allowing them to receive net proceeds from the sale of its legacy biosimilar assets. This move completes the company's transformation into a focused, innovative immuno-oncology company. The CVRs will be non-transferable and will expire on October 7, 2028, with payments contingent on the successful monetization of these biosimilar assets.

    GlobeNewswire•8/18/26•
    Somewhat-Bullish

    Form 8K Coherus BioSciences Inc For: 17 August By Investing.com

    This article reports on a Form 8K filing by Coherus BioSciences Inc for August 17. The brief piece primarily serves as an announcement for the filing, linking to Reuters for more details. It also includes general market data and other popular news headlines.

    Investing.com Canada•8/18/26•
    Neutral

    Form 8K Coherus BioSciences Inc For: 17 August By Investing.com

    Investing.com reports that Coherus BioSciences Inc. filed a Form 8K for August 17th. The article provides this basic information along with market data, news headlines, and various financial tools available on the Investing.com platform. Coherus BioSciences (CHRS) stock is noted with a +16.52% change.

    Investing.com Nigeria•8/17/26•
    Neutral

    Form 8K Coherus BioSciences Inc For: 17 August By Investing.com

    This article reports on a Form 8K filing by Coherus BioSciences Inc. for August 17. The brief announcement from Investing.com indicates that the filing was made on this date. Coherus BioSciences Inc. (CHRS) saw a stock price change of -4.17%.

    Investing.com UK•8/17/26•
    Neutral

    Coherus BioSciences, Inc. (CHRS) stock price, news, quote and history

    Coherus Oncology, Inc. (CHRS), formerly Coherus BioSciences, Inc., is a biopharmaceutical company focused on researching, developing, and commercializing immunotherapies for cancer. The article provides a detailed financial overview, including stock performance, key metrics like market capitalization and P/E ratio, and analyst ratings. It also lists the company's product pipeline, collaboration agreements, and comparative data with other biotechnology firms.

    Yahoo Finance UK•8/7/26•
    Somewhat-Bullish

    Frequently Asked Questions About CHRS

    Does CHRS pay dividends?
    Coherus BioSciences Inc (CHRS) does not currently pay a regular dividend.
    What is CHRS's market cap?
    Coherus BioSciences Inc (CHRS) has a market capitalization of $208.58M with a current stock price of $1.35.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In